Zenith Epigenetics Ltd

6 articles about Zenith Epigenetics Ltd

• Zenith Epigenetics Announces Start of Several National Cancer Institute (NCI)-Sponsored Oncology Clinical Trials

  7/6/2022

  Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today that its leading BET inhibitor, ZEN-3694, is being evaluated in seven NCI sponsored clinical trials for safety and efficacy in multiple oncology indications with significant unmet need, through the NCI’s Cancer Therapy Evaluation Program (CTEP).

• Zenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the American Society of Clinical Oncology Conference (ASCO)

  6/21/2022

  Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today that the data from its Phase 2 Metastatic Triple Negative Breast Cancer (mTNBC) clinical trial combining ZEN-3694 + Pfizer Inc.’s Talzenna (talazoparib) was highlighted at an oral session “Optimizing Targeted Therapies in Advanced Breast Cancer: Building on Past Success”.

• 

  Clinical Catch-Up: Updates for Achilles, Logic Bio, Roche and More

  5/16/2022

  Achilles dosed the first patient in a Phase I/IIa advanced NSCLC trial, Logic Bio's pediatric methylmalonic acidemia study is back up and running and another look at Roche's TIGIT flop.

• Zenith Epigenetics Announces Initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) Clinical Trial

  5/10/2022

  Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today the initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) clinical trial combining ZEN-3694 + Pfizer Inc.’s Talzenna (talazoparib).

• Zenith Epigenetics Announces Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb’s Immune Checkpoint Inhibitor OPDIVO

  2/22/2022

  Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today the dosing of a first patient with a combination of ZEN-3694 (BET inhibitor) + Bristol Myers Squibb’s PD-1 immune checkpoint inhibitor OPDIVO and YERVOY, in a National Cancer Institute (NCI), part of the National Institutes of Health, sponsored trial in solid tumor cancer.

• Zenith Epigenetics Announces Appointment to Board of Directors and Provides Clinical Update

  1/31/2022

  Zenith Capital Corp. (“Zenith” or the “Company”) today announced the appointment of Dr. Brad Thompson, PhD, to its board of directors.